At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PODD Insulet
Market Closed 11-06 16:00:00 EST
146.51
-9.61
-6.16%
盘后146.86
+0.35+0.24%
19:58 EST
High155.60Low143.28Vol1.57M
Open155.60D1 Closing156.12Amplitude7.89%
Mkt Cap10.15BTradable Cap10.12BTotal Shares69.26M
T/O229.04MT/O Rate2.27%Tradable Shares69.07M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Insulet Corp. Stock Sheds 6.2%, Underperforms Peers
Dow Jones  ·  05:35
Insulet Corp. Stock Sheds 6.2%, Underperforms Peers
Movement Alert｜Insulet Falls 5.84% in Regular Trading, Valuation Digestion Follows Recent Earnings Beat and More Cautious Long-Term Outlook
Market Focus  ·  11-06 23:04
Movement Alert｜Insulet Falls 5.84% in Regular Trading, Valuation Digestion Follows Recent Earnings Beat and More Cautious Long-Term Outlook
Tandem Diabetes Q3 Sales Rise on International Growth; Reaffirms 2026 Outlook
Reuters  ·  11-06 05:49
Tandem Diabetes Q3 Sales Rise on International Growth; Reaffirms 2026 Outlook
Insulet Sees Attractive Valuation Despite More Conservative 2027 Outlook, RBC Says
MT Newswires Live  ·  11-06 01:49
Insulet Sees Attractive Valuation Despite More Conservative 2027 Outlook, RBC Says
Movement Alert｜Insulet Falls 5.16% in Regular Trading, post-earnings pullback follows cautious target-price update
Market Focus  ·  11-06 00:26
Movement Alert｜Insulet Falls 5.16% in Regular Trading, post-earnings pullback follows cautious target-price update
Insulet is Maintained at Equal-Weight by Wells Fargo
Dow Jones  ·  11-05 23:25
Insulet is Maintained at Equal-Weight by Wells Fargo
Leerink Partners Adjusts Insulet Price Target to $167 From $143
MT Newswires Live  ·  11-05 20:40
Leerink Partners Adjusts Insulet Price Target to $167 From $143
Teleflex Q3 Revenue Slightly Beats Estimates
Reuters  ·  11-05 19:47
Teleflex Q3 Revenue Slightly Beats Estimates
Enovis Q3 EPS Beats Estimates; Raises FY Profit Outlook
Reuters  ·  11-05 19:16
Enovis Q3 EPS Beats Estimates; Raises FY Profit Outlook
Insulet Corporation : TD Cowen Raises Target Price to $163 from $144
THOMSON REUTERS  ·  11-05 15:05
Insulet Corporation : TD Cowen Raises Target Price to $163 from $144
Insulet Corporation : RBC Raises Target Price to $180 from $160
THOMSON REUTERS  ·  11-05 11:58
Insulet Corporation : RBC Raises Target Price to $180 from $160
Insulet Corp. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  11-05 06:13
Insulet Corp. Stock Outperforms Competitors on Strong Trading Day
Insulet price target raised to $200 from $175 at Baird
TIPRANKS  ·  11-05 03:50
Insulet price target raised to $200 from $175 at Baird
Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share
Benzinga Earnings  ·  11-05 03:21
Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share
Insulet Climbs After Quarterly Results Beat
Reuters  ·  11-05 00:27
Insulet Climbs After Quarterly Results Beat
Movement Alert｜Insulet Intraday Rise 5.25% in Regular Trading, Q3 Beat and $1 Billion Buyback Support Shares
Market Focus  ·  11-05 00:25
Movement Alert｜Insulet Intraday Rise 5.25% in Regular Trading, Q3 Beat and $1 Billion Buyback Support Shares
Insulet Targets 2028 Launch of Fully Closed-Loop Insulin Delivery System for Type 2 Diabetes
Reuters  ·  11-05 00:22
Insulet Targets 2028 Launch of Fully Closed-Loop Insulin Delivery System for Type 2 Diabetes
Insulet Corporation Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  11-04 23:07
Insulet Corporation Reports Results for the Quarter Ended September 30 - Earnings Summary
Insulet Q3 Adjusted Earnings, Revenue Rise; 2026 EPS Outlook Maintained
MT Newswires Live  ·  11-04 20:39
Insulet Q3 Adjusted Earnings, Revenue Rise; 2026 EPS Outlook Maintained
Insulet Reports Strong Third-Quarter Growth and Margin Expansion
TIPRANKS  ·  11-04 20:39
Insulet Reports Strong Third-Quarter Growth and Margin Expansion

Introduction

Company Name.
Insulet
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Issue price:
--